Punam Malik, MD
- Director, Cincinnati Comprehensive Sickle Cell Center
- Program Leader, Hematology and Gene Therapy Program
- Marjory J. Johnson Chair, Gene and Cell Therapy
- Professor, UC Department of Pediatrics
- punam.malik@cchmc.org
- Board Certified
About
MBBS: University of Delhi, New Delhi, India, 1985.
MD: University of Delhi, New Delhi, India, 1989.
MS: University of Maryland, Baltimore, MD, 1991.
Fellowship: Children's Hospital Los Angeles, University of Southern California, 1995.
Services and Specialties
Cancer and Blood Diseases, Sickle Cell and Hemoglobin Disorders
Research Areas
Experimental Hematology and Cancer Biology, Cancer and Blood Diseases, Hematology
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Preclinical safety assessment of modified gamma globin lentiviral vector-mediated autologous hematopoietic stem cell gene therapy for hemoglobinopathies. PloS one. 2024; 19:e0306719.
NRASQ61R mutation drives elevated angiopoietin-2 expression in human endothelial cells and a genetic mouse model. Pediatric Blood and Cancer. 2024; 71:e31032.
CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model. Blood Advances. 2024; 8:947-958.
Generation of a tyrosine hydroxylase-2A-Cre knockin non-human primate model by homology-directed-repair-biased CRISPR genome editing. Cell Reports: Methods. 2023; 3:100590.
Strategies for precise gene edits in mammalian cells. Molecular Therapy-Nucleic Acids. 2023; 32:536-552.
CRISPR/Cas9 Gene Editing of MIR155HG in Primary Human T Cells to Prevent Acute Graft-Versus-Host Disease. Journal of immunology (Baltimore, Md. : 1950). 2023; 210:173.21.
Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI). Gene Therapy (Basingstoke). 2023; 30:216-221.
Future Directions and Resource Needs for National Heart, Lung, and Blood Institute (NHLBI) Gene Therapy Research: A Report of an NHLBI Workshop. Human Gene Therapy. 2023; 34:83-89.
Preclinical Evaluation of Foamy Virus Vector-Mediated Gene Addition in Human Hematopoietic Stem/Progenitor Cells for Correction of Leukocyte Adhesion Deficiency Type 1. Human Gene Therapy. 2022; 33:1293-1304.
CRISPR/CAS9 Gene Editing of MIR155HG in Primary Human T Cells to Prevent Acute Graft-Versus-Host Disease. Blood. 2022; 140:10200-10201.
From the Blog
Preventing Adult Sickle Cell Deaths From Kidney Disease May Start With Improved Childhood Testing
Punam Malik, MD, Omar Niss, MD4/15/2020
Gene Therapy Advances Raise Hopes for Curing Sickle Cell Disease
Punam Malik, MD6/27/2019
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey